Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

14 questions · 14 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

No studies found 1 · 7.1%GRADE not reported 0 · 0%Very low 7 · 50%Low 0 · 0%Moderate 6 · 42.9%High 0 · 0%

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Overall survival: Median length of · women with advanced EOC after primary IDS

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).

1 finding from 1 review

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Progression‐free survival · women with advanced EOC after primary IDS

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).

1 finding from 1 review

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Overall survival: Median length of · women with advanced ovarian cancer after PDS

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

1 finding from 1 review

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Progression‐free survival · women with advanced ovarian cancer after PDS

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

1 finding from 1 review

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Overall survival: Median length of · women with advanced EOC after PDS

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).

1 finding from 1 review

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Progression‐free survival · women with advanced EOC after PDS

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).

1 finding from 1 review

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Overall survival: Median length of · women with advanced EOC after primary IDS

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with no macroscopic residual disease (NMRD) (very low certainty).

1 finding from 1 review

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

Overall survival: Median length of · women with advanced EOC after PDS

Small‐volume residual disease (SVRD) < 1 cm probably leads to higher overall survival: Median length of compared with NMRD (moderate certainty).

1 finding from 1 review

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

Progression‐free survival · women with advanced EOC after PDS

Small‐volume residual disease (SVRD) < 1 cm probably leads to higher progression‐free survival: Median length of compared with NMRD (moderate certainty).

1 finding from 1 review

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

Overall survival: Median length of · women with advanced EOC after primary IDS

It is very uncertain whether small‐volume residual disease (SVRD) (< 1 cm) changes overall survival: Median length of compared with NMRD (very low certainty).

1 finding from 1 review